Subject company
Pfizer Inc.
Director, Clinical Data Science · Global Job Level 11 · Cambridge, MA
Accept the offer; negotiate specifically and exclusively on equity grant size. The base is at ceiling for this market, making a push from $55,000 toward $75,000–$80,000 in RSUs the highest-leverage ask available before the October 15 start date.
Pfizer Inc.: Structurally strong base at market ceiling — equity grant is the single negotiation lever worth pressing.
Offer vesting schedule
Data Scientists · Level IV · Massachusetts
This offer’s base sits at the 90th percentile — above nearly every certified filing in this band.
Your base: $215,000 · $27,026 above the P75 mark — this band is a floor under you, not a ceiling
Source: DOL OFLC LCA disclosure data · n=203 certified filings · base cash only (excludes equity and bonus). Use as a citable market floor, not total compensation.
The negotiation room this brief is built to unlock — typically many multiples of its price. The lever-by-lever play is in the negotiation playbook below.
Solid
company trajectory · high confidence
5-year expected total comp (probability-weighted NPV)
What moves this number
Discount rate: 10%
Vesting over 3 years with 1-year cliff
Bear equity multiple: 0.3x
Base equity multiple: 1.0x
Bull equity multiple: 2.5x
Exit probabilities: bear 30%, base 50%, bull 20%
What to do next
Start here. This section compresses the brief into the decision, the strongest reasons behind it, and the risks that deserve verification before you sign.
Why the verdict landed here
Base $215,000 sits at the 90th percentile of the base-cash market band (median $162,634).
Company operating quality is middling (Rule of 40: 23.5).
Signals we only see when the data is connected
The 14,000-person restructuring wave has not spared R&D-adjacent functions, yet the five-year base case assumes stable Director-level headcount — creating a gap between the narrative and the structural risk facing this role
highRisks + Career upside + Company quality · medium confidence · 2 source facts in the appendix
Pfizer's AI embedding priority is the primary lever for scope negotiation, but three strategic themes — margin expansion, streamlining operations, and maximizing commercial portfolio value — have vanished from earnings language without resolution, raising the risk that Clinical Data Science AI investment is next to be quietly deprioritized
highCompany quality + Questions to ask + Negotiation leverage · medium confidence · 2 source facts in the appendix
The RSU grant is priced at a reasonable entry point relative to DCF fair value, but the 6.9% dividend yield, a Rule of 40 score of 24, and a 12-month max drawdown of -17.1% collectively signal a capital-return-first company where equity appreciation sufficient to make the $55K grant meaningful is structurally unlikely over the three-year vest window
mediumOffer economics + Company quality + Negotiation leverage · high confidence · 3 source facts in the appendix
The CFO departure and interim leadership gap coincide with an unresolved $4.5B cost-savings program — meaning the executive most responsible for budget allocation to the Clinical Data Science AI build will be an interim appointee during the candidate's first six months, precisely when headcount and infrastructure commitments are set
highLeadership and stability + Risks + Questions to ask · medium confidence · 3 source facts in the appendix
Unlock 3 more signals only Footnote connects
Live SEC filings, peer comp, scripts, provenance, and canonical synthesis — built for your company and offer.
Get the Offer Brief — $49See all four brief tiersScore components
Bar color: strong (65+) · moderate (45–64) · weak (<45)
Higher is healthier on every bar — including Red flags, where a high score means few were raised
Purchase your report to unlock full details
Live SEC filings, peer comp, scripts, provenance, and canonical synthesis — built for your company and offer.
Get the Offer Brief — $49See all four brief tiersThe decision rule
Accept-leaningDerived from this brief’s own numbers — the band placement, company operating quality, and role exposure — not model judgment. The same rule fixes the verdict above.
- Comp is already placed above market — protect it; negotiate scope, level, or refresh terms instead of base.
- The equity-weighted package (base plus equity plus signing) stays ≥ 1.5× the base-cash median (currently 1.8×).
- Equity is the swing factor — confirm the refresh policy and vest mechanics before relying on the headline number.
- Verification surfaces a dealbreaker (the verification questions in the negotiation playbook) — scope, level, or team stability materially worse than represented.
Alumni outcomes require optional user-contributed career data and confidence thresholds.
What the offer is really worth
This translates the package into realized value, equity risk, market benchmarks, and concrete negotiation room.
base plus equity plus signing
Market consensus
A compact read on whether public-market expectations support the equity story behind the offer.
BMO Capital: maintain
Jul 13, 2026 · Outperform → Outperform
Guggenheim: maintain
Jul 13, 2026 · Buy → Buy
B of A Securities: maintain
Jul 10, 2026 · Neutral → Neutral
JP Morgan: maintain
Jul 08, 2026 · Neutral → Neutral
The $215K base already sits at the 90th percentile of the DOL H-1B/LCA Massachusetts band (median $162,634, n=203) and well above the BLS OEWS Massachusetts median for Data Scientists of $131,750 — base is effectively at ceiling for this market, so the negotiation surface is almost entirely on the equity side: the $55K RSU grant (3-year vest, bear/base scenario $59,246 at analyst consensus $27) is thin relative to the role scope and Pfizer's own R&D strategic priority around AI and clinical data, where the earnings transcript explicitly names AI embedding as a key priority. The CFO departure (Dave Denton out August 15, Cecile Guegan interim) and the sigvotatug Phase 3 miss introduce near-term headline risk, but the DCF fair value of $38.37 versus the current $25.07 price — and the analyst median target of $27 — suggest the RSU grant price is a reasonable entry point if you can negotiate the grant size up 10–15% (to roughly $60–65K face value), which is the primary lever worth pressing before the October 15 start date. Equity scenarios use rsu linear and show 54.3% spread across available public valuation anchors.
Evidence confidence: high
RSU Grant Is Thin; Push for More: The $55,000 RSU grant vesting over 3 years yields roughly $18,333 per year at current prices — a modest equity stake for a Global Job Level 11 director at a $142B company. PFE's DCF fair value is modeled at $38.37 versus the current price of $25.07, implying 53% upside to intrinsic value; even the analyst consensus target of $27 represents 7.7% appreciation. Request a grant increase to $80,000–$90,000 and frame it as alignment with the company's own recovery thesis — you're being asked to absorb current-price risk on a stock down 12.2% from its recent peak.
Evidence confidence: medium
Base Is Strong; Redirect Energy to Signing Bonus: At $215,000, your base sits at the 90th percentile of the Massachusetts base-cash market band (median $162,634, n=203 DOL LCA filings). That ceiling limits upside from pushing base further without triggering internal equity concerns at Pfizer's banding structure. The more productive ask is increasing the signing bonus from $30,000 to $45,000–$50,000, which is a one-time cost Pfizer can book outside the salary band and which compensates for unvested equity or deferred comp you are leaving behind at your current employer.
Evidence confidence: medium
AI Priority Creates Scope Negotiation Leverage: Pfizer's Q1 2026 earnings call explicitly named AI as a key strategic priority — 'embedding the use of artificial intelligence across our company' in R&D, commercial, manufacturing, and enterprise functions. A Director of Clinical Data Science sitting at the intersection of AI and clinical R&D is directly on the critical path of that stated priority. Use this to negotiate explicit scope language: request that the offer letter or role charter reference AI/ML platform responsibilities, which strengthens your case for a Level 12 reclassification review within 12–18 months of start.
Evidence confidence: medium
Per the 2026 DEF 14A proxy, CEO Albert Bourla received $27.6M total comp in 2025 ($1.8M salary, $9.4M stock awards, $9.0M option awards, $5.4M incentive plan); CSO Chris Boshoff received $7.9M in 2024 with $1.2M base — establishing that Pfizer's R&D leadership carries heavy equity weighting (stock + options = ~40–50% of total package at the SVP/EVP tier). The Director-level offer of $215K base with $55K RSU sits well below the named-executive tier but is consistent with Pfizer's pattern of front-loading base cash at senior individual-contributor levels while keeping equity grants modest relative to total comp.
From proxy-statement compensation records.
The 90-day insider window shows 1 open-market sell and 0 open-market buys, classified as opportunistic_selling with low signal strength; the 13 equity award rows are non-discretionary grants, not conviction purchases. Materialized signal facts confirm Bourla's recent transactions are award-type (option_exercise_hold, positive classification), meaning no named executive has made a discretionary open-market purchase — a neutral-to-cautious read on near-term stock conviction at the $25 price level.
Pattern read derived from Form 4 filing data.
Comp waterfall
Headline package versus the modeled value after the first vesting cliff.
It separates advertised compensation from what is actually exposed to vesting timing.
Anchor negotiation around the gap between headline value and first-year realized value.
Equity scenarios
Cliff risk: leave before the first vesting cliff and realized equity is $0 — the bear case is not the floor. Weigh signing cash accordingly.
Bear, base, and bull public-market anchors for the equity grant.
RSU value is not fixed. A strong offer can still carry material downside if the stock resets.
Ask for equity refresh protection, a higher grant, or signing cash if downside exposure is high.
Directional public-market anchors — not company-specific exec comp or your offer.
Massachusetts · n=203 · offer at 90th pct
- P10
- $148,762
- P25
- $148,762
- Median
- $162,634
- P75
- $187,975
- P90
- $214,900
Base cash only (year) — excludes equity and bonus.
BLS OEWS floor — Data Scientists, Massachusetts (state OEWS) (2025): median $131,750. Government survey median; a conservative floor, not the role-and-metro market the band above reflects.
Peer tickers are selected from public market data and filings — use as directional context, not a compensation survey.
Not available for this run: next earnings date. Every stream we checked — rendered, held, or absent — is itemized in the appendix coverage matrix.
Growing — new sponsored-hire approvals rose in the latest complete fiscal year. Denial rate across the window: 1.1%. Still actively attesting: 81 certified LCA filings in FY2025 — the freshest read on sponsorship intent, ahead of the slower petition record.
Petition approvals from the federal record — counts of approvals, not people; one person can hold multiple petitions across years. LCA filings are attestations, not hires. A fiscal year marked “prelim.” is still being published by USCIS and is left out of the trend. Read the trend, not the absolute size.
This employer sponsors a 401(k) plan in the federal benefit-plan record. Headcount and the match below read from its retirement plan on file — PFIZER SAVINGS PLAN.
Audited DOL Form 5500 filings for FY2024, which lag the calendar by roughly one to two years. Counts are PLAN PARTICIPANTS — covered employees plus separated staff still holding a balance — not a headcount, and are read from the single representative retirement plan, never summed across a sponsor’s plans. Employer contributions are the plan’s Schedule H line 2a (the match); a blank contribution line means it was not disclosed at this grain, not that it was zero. The absence of a line is never the absence of the benefit.
Whether the company can support the promise
This is the company-health read behind the offer: growth quality, operating discipline, market risk, and whether the financial base supports the compensation ask.
Revenue mix
Biopharma Segment
Segment Reporting, Reconciling Item, Corporate Nonsegment
Latest reported segmentation, period as filed · USD. Panels may cover different filing periods — do not total one against the other.
Where geographic revenue comes from
UNITED STATES
Developed Rest Of World
Emerging Markets
Latest reported segmentation, period as filed · USD. Panels may cover different filing periods — do not total one against the other.
Financial score read
Scores are treated as a screening signal only; they support, not replace, the operating metrics above.
Recent events that change the read
2 Absurdly Cheap Healthcare Stocks to Buy Before July Ends
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
Source feeds are filtered to a short materiality read; the brief avoids raw news-feed dumps.
Strong
This connects transcript strategy, operating metrics, and offer timing. A coherent company story strengthens equity confidence; drift or mixed messaging shifts emphasis toward cash certainty and explicit role scope.
The offer is structurally strong: base of $215,000 sits at the 90th percentile of the Massachusetts base-cash market band (median $162,634, n=203), and the $300,000 headline package is 1.8× that median — though that comparison is only valid because the band excludes equity and bonus. The RSU grant of $55,000 over three years is the negotiation gap: at a current price of $25.07 against a DCF fair value of $38.37 and analyst median target of $27, the equity is modestly underwater on a risk-adjusted basis, and Pfizer's stock has returned only 3.3% over the past 12 months versus peer-group revenue growth of 5.5% (Pfizer's own YoY revenue growth: 5.4%) — making a push for a larger initial RSU tranche or an accelerated cliff the highest-leverage ask. The CFO departure (Dave Denton out August 15, interim Cecile Guegan named), a missed Phase 3 lung cancer trial for sigvotatug vedotin, and active LNP patent litigation from Arbutus are real headline risks, but Pfizer's reaffirmed 2026 guidance of $59.5–$62.5 billion in revenue and a 6.9% dividend yield suggest the company is not in financial distress — this is a restructuring-era employer, not a distressed one, and the role warrants acceptance with targeted equity and scope negotiation.
Evidence confidence: medium
Rule of 40 score 24 — revenue growth 5.4% plus FCF margin 18.1%.
Evidence confidence: high
Annualized volatility 24.4%; max 12-month drawdown -17.1%; current drawdown -12.2%.
Evidence confidence: high
Strategic coherence: 75/100 (Strong). The strategic narrative shows a consistent focus on R&D, oncology, and AI integration, with a clear evolution in themes across quarters.
Evidence confidence: high
Consistent themes across quarters: Oncology, AI Integration, R&D Productivity.
Evidence confidence: high
Themes that vanished without resolution: Maximizing commercial portfolio value, Expanding margins, Streamlining operations.
Evidence confidence: medium
Disappeared themes may indicate strategic pivot or de-prioritization.
Newly appeared themes: Innovation and Growth, Acquisition Strategy, Cost Management, Leadership in next-generation therapies, Investing in post-2028 growth.
Evidence confidence: medium
Strong focus on R&D and innovation suggests opportunities for growth in roles related to these areas.
Evidence confidence: high
Reported lobbying spend of $20.39M across 40 LDA/SOPR filings (24 months). Primary issue codes: HCR (17), TRD (17), TAX (16), MMM (8), PHA (6).
$0.02M in federal obligations across 20 USAspending awards (24 months). Largest agencies: Department of Defense ($0.02M).
In their own words
Verbatim from the latest earnings call — management’s stated risks and investment priorities, unedited.
“While we remain focused on managing near-term LOE headwinds, we are actively building the foundation for durable long-term value creation.”
“Sustained low disease levels of COVID will likely continue to weigh on Paxlovid utilization over the next several months.”
“Roughly half of our anticipated key data readouts and regulatory decision in 2026 are expected to come from oncology.”
“We are targeting approximately 20 pivotal study starts, 8 key data readouts and 4 regulatory decisions this year.”
Rule of 40
Growth plus margin sits below the 40 line — growth is coming at the cost of margin (or vice versa). Lean toward cash and role-scope certainty over back-loaded equity.
Revenue growth and free-cash-flow margin combined into an operating-quality score.
It gives a quick read on whether growth is disciplined or being bought with weak margins.
Use a strong score as support for a stronger equity or refresh ask.
Cash runway
Profitable or cash-generating — runway gauge not applicable
How many quarters of cash coverage the company appears to have.
Cash stress changes negotiation posture and role risk.
If runway is thin, prefer cash/signing certainty over back-loaded equity.
Revenue per employee
Revenue productivity per employee from company financial and headcount data.
High productivity supports premium compensation; weak productivity can foreshadow cost pressure.
Use strong productivity as support for a strategic-hire compensation argument.
Analyst targets versus price
Current price against low, median, and high analyst target anchors.
It frames whether the market already prices in most of the upside.
Use wide dispersion as a reason to derisk vesting or ask for more shares.
Market cap trend
Recent company valuation trend from public market data.
It contextualizes equity timing and whether the offer arrives after a run-up or reset.
Pair this with stock-risk metrics before accepting equity-heavy compensation.
What could make this role better or worse than it looks
This section turns leadership, insider, board, and market signals into career-risk context for the role you are considering — and carries the forward scenarios: the base case and the three forks this offer can take.
0 = insulated · 100 = high · a separate read from company health
Some exposure: revenue trend (segment proxy) is the main flag to verify.
1 WARN notice for this employer in the last 12 months (~100 workers). · source
Company revenue is down 19% across the available quarters — a coarse proxy when segment-level revenue is not disclosed.
1 executive departure in the last 12 months. · source
Concluded U.S. DOL Wage & Hour cases, matched to this employer by name and aggregated. A clean record here is not a guarantee; a case filed under a differently-spelled entity may not be captured.
1 concluded U.S. DOL Wage & Hour case on record (most recent findings 2007-12-14).
U.S. OSHA inspection and citation history, matched to this employer by establishment name and aggregated. Most relevant for on-site, warehouse, or operational roles; a clean or empty record is common for office employers and is not a guarantee.
23 U.S. OSHA inspections on record across 9 states (most recent 2009-04-17).
Litigation (public court records)
None in the record
Wage enforcement (U.S. DOL WHD)
On file — see detail above
Workplace safety (U.S. OSHA)
On file — see detail above
DOL debarment
None in the record
Limitations
No Item 2.05 restructuring 8-Ks matched this employer in the lookback window.
No public ATS board is mapped for this employer, so hiring velocity is unavailable.
Public court-records lookup degraded this run — litigation posture may be incomplete.
Segment-level revenue is rarely disclosed; the revenue signal uses the company total as a proxy.
Leadership graph (resolved): Cecile Guegan — Interim Chief Financial Officer (since 2026-08-16); Michael McDermott — Chief Global Supply and Quality Officer, Executive Vice President (since 2025-01-01); Douglas Lankler — Executive Vice President & Chief Legal Officer (since 2025-01-01); Chris Boshoff, MD, FRCP, FMedSci, Ph.D. — Chief Scientific Officer and President, Research & Development (since 2025-01-01); Andrew Baum, MA, BM ChB — Chief Strategy and Innovation Officer and Executive Vice President (since 2024-01-01); Aamir Malik — Executive Vice President & Chief U.S. Commercial Officer (since 2023-01-01); Alexandre de Germay — Chief International Commercial Officer, Executive Vice President (since 2023-01-01); Payal Sahni — Chief People Experience Officer, Executive Vice President (since 2022-01-01); David Denton — Executive Vice President & Chief Financial Officer (since 2022-01-01); Lidia Fonseca — Chief Digital and Technology Officer, Executive Vice President (since 2019-01-01); Albert Bourla, DVM, Ph.D. — Chief Executive Officer (since 2019-01-01); Payal Sahni Becher — Chief People Experience Officer & Executive Vice President
Evidence confidence: medium
Echevarria Joseph: option_exercise_hold (neutral).
Evidence confidence: medium
Buckley Mortimer J: option_exercise_hold (neutral).
Evidence confidence: medium
BOURLA ALBERT: option_exercise_hold (positive).
Evidence confidence: medium
BOURLA ALBERT: option_exercise_hold (positive).
Evidence confidence: medium
BOURLA ALBERT: option_exercise_hold (positive).
Evidence confidence: medium
Cecile Guegan hire: Interim Chief Financial Officer
Evidence confidence: medium
By mid-2028, Pfizer's ongoing restructuring — which already eliminated 14,000 positions between FY2023 and FY2025 — reached the Clinical Data Science organization in Cambridge. The interim CFO who replaced Dave Denton in August 2026 approved a second wave of R&D cost reductions tied to the Arbutus LNP litigation settlement reserve and a slower-than-expected oncology pipeline conversion rate, and the Director-level Clinical Data Science headcount in Cambridge was cut from 12 to 7. The user's role was either eliminated outright or so severely scope-reduced — stripped of the AI/ML pipeline ownership that made the role attractive — that it became a data governance maintenance function, triggering a voluntary exit inside the 12-month signing bonus clawback window and forcing repayment of $30,000 at the worst possible moment.
Evidence confidence: medium
Pfizer announces a second WARN Act filing in Massachusetts or a Cambridge-specific headcount reduction in Clinical Data Science or the broader Digital and Technology organization before April 2027 — monitor the Massachusetts WARN Act database…
Evidence confidence: medium
The permanent CFO search extends beyond Q1 2027 without a named hire, or the incoming permanent CFO's first public action includes a revised 2027 cost-savings target above the existing $4.5B program — watch Pfizer 8-K filings and earnings call transcripts for any upward revision to the…
Evidence confidence: medium
The $215,000 base lands at the 90th percentile of the Massachusetts base-cash market band (median $162,634, n=203 DOL filings), giving you a structurally superior starting position before a single dollar of equity or bonus is counted. The headline package of $300,000 — base plus $55,000 RSI grant plus $30,000 signing — is 1.8× the base-cash median, though that multiple is not directly comparable to the band since the band excludes equity and bonus entirely. Negotiate from strength on equity: the DCF fair value of $38.37 against a current price of $25.07 implies 53% upside, and pushing the RSU grant from $55,000 toward $75,000–$80,000 is a credible ask given Pfizer's 2026 full-year revenue guidance of $59.5–$62.5 billion and three positive Phase III readouts already in hand this year.
Evidence confidence: medium
Career-path aggregates use optional user contributions; this report scores public filings only.
SEC leadership records alumni reference: 2 executive transitions; top buckets: other (1), departure (1).
Evidence confidence: medium
Three forks
The three ways this role can go from here — the downside path, the base case, and the upside. Each fork carries a signal of its own direction or says plainly that none was extracted; a fork never borrows the nearest available sentence.
Pfizer announces a second WARN Act filing in Massachusetts or a Cambridge-specific headcount reduction in Clinical Data Science or the broader Digital and Technology organization before April 2027 — monitor the Massachusetts WARN Act database…
The $215,000 base lands at the 90th percentile of the Massachusetts base-cash market band (median $162,634, n=203 DOL fi
A 'no' answer — any net reduction in permanent Director-level headcount in this specific org — confirms the restructuring wave has already reached the user's peer group and the role is structurally…
Leadership tape
Source-backed leadership facts are used conservatively; unresolved or sparse records are omitted from user-facing claims.
Cecile Guegan
2026-08-16hire: role → Interim Chief Financial Officer
“will serve as Interim Chief Financial Officer”
Dave Denton
2026-08-15departure: Chief Financial Officer → role
“he will step down from his current position as Chief Financial Officer”
Coverage note
Insider intensity
Form 4 buy/sell activity summarized by month.
Heavy selling does not automatically mean distress, but it changes how much equity risk you should accept.
Use sustained selling as support for vest protection or more cash.
Institutional ownership
3,059 institutional holders (latest 13F)
How much of the float sits with institutions, and across how many holders.
Ownership mix can amplify volatility and market sensitivity.
Treat concentrated ownership as another reason to stress-test equity-heavy offers.
Not available for this run: dated C-suite tenure, board interlocks, and largest-holder position sizes. Every stream we checked — rendered, held, or absent — is itemized in the appendix coverage matrix.
Employer durability versus peers
How this company's financial health reads against its public peers — every company scored on the identical rubric, from its own filings. This is a durability comparison, not a list of jobs you could take instead.
Financial health, one rubric
Every company below is scored by the same rule — Rule of 40, revenue growth, cash runway — from its own filings. No cross-company guessing.
Financial health on one rubric: PFE scores 53; peers — AMGN 58, DHR 57, BSX 53, BMY 45; peer median 57.
Evidence confidence: medium
Financial-health axis only — leadership, career, and role factors are not honestly comparable across companies from public filings alone.
No user-contributed tenure aggregate has passed k-anonymity for this company yet.
Evidence confidence: low — read the specifics as directional, not verified
How to use the brief in the conversation
This is the action layer: the asks to prioritize, the scripts to use, the questions to ask, and the dealbreakers to monitor.
Your base of $215,000 is already strong — it's at the top of what the market data shows for this role in Massachusetts, so that's not where to spend your energy. The real gap is in equity: $55,000 over three years is thin for a director-level role at a company this size, especially when you're being asked to absorb current stock-price risk. Open by expressing genuine enthusiasm for the role and the team, then make one clean ask: bring the RSU grant to $63,000. If they push back on equity, pivot to the signing bonus as a one-time bridge. Keep the conversation warm and collaborative — you want this job, and the recruiter knows it. Negotiate from confidence, not desperation.
Your counter, lever by lever
At $215,000, the offer is already at approximately the 90th percentile of the Massachusetts base-cash market band (median $162,634, p75 $187,975, n=203 DOL LCA filings). The target of $226,000 is a modest 5% push that tests whether the band has room, but the floor is $215,000 — do not sacrifice equity or signing concessions to move base by a few thousand dollars. The primary value of raising this ask is to signal seriousness and create room to trade back to equity.
offer at/above market p90 — small base push, press equity & scope
The current $55,000 RSU grant vesting over 3 years yields roughly $18,333 per year at a stock price of $25.07 — a thin equity stake for a Global Job Level 11 director at a $142B company. The target of $63,000 represents a 15% increase and is the primary ask. The equity scenario base case values the grant at $59,246 at the analyst consensus price of $27; the bull case reaches $91,436 only at $41.67. The DCF fair value is modeled at $38.37 against a current price of $25.07, meaning the candidate is being asked to absorb current-price risk on a stock down 12.2% from its recent peak — a larger grant is fair compensation for that timing risk.
computed equity room
The current $30,000 signing bonus is the floor; the target of $11,000 additional (to $41,000) is a one-time bridge sized to the annualized base gap if the company cannot move base. Signing bonuses are booked as one-time costs outside the salary band, making them easier for Pfizer to approve without triggering internal equity concerns. This is the fallback lever: if equity and base are both immovable, a signing increase to $41,000 partially compensates for unvested equity or deferred comp left behind at the prior employer, and the clawback conversation (request 6-month window or involuntary-termination carve-out) should accompany this ask.
one-time bridge sized to the base gap (use if they cannot move base)
Pfizer's Q1 2026 earnings call named AI as a key strategic priority — embedding it across R&D, commercial, manufacturing, and enterprise functions. A Director of Clinical Data Science at the intersection of AI and clinical R&D is directly on that critical path. The scope ask costs Pfizer nothing today: request that the role charter or offer letter explicitly reference AI/ML platform responsibilities. This language strengthens the case for a level reclassification review within 12–18 months and sets the foundation for an equity refresh at a higher grant level. It also signals that you've done your homework on where the company is going.
non-cash lever: leveling, scope, and equity-refresh cadence
Scripts
Written to be sent as they are. Edit any of them before you copy.
When they push back
“The base is already above our band for this level — we don't have room to move it.”
That makes complete sense, and honestly the base isn't my main focus. What I'd really like to work on is the equity grant. Can we look at getting the RSUs to $63,000?
“The equity grant is set by the job level — we can't change it outside of the standard range.”
I understand there's a structure, and I respect that. If the grant itself is fixed, would it be possible to look at the signing bonus as a bridge? Getting that to $41,000 would go a long way toward making this work for me.
“We don't have flexibility on the signing bonus either — $30,000 is what we have approved.”
I hear you. Let me ask a different question then — is there anything we can do on the scope side? I'd love to have the role charter reflect the AI and data platform work explicitly, and I'd want to understand what a level review looks like at the 12 or 18 month mark. That kind of clarity would mean a lot to me.
“This is our best and final offer.”
I appreciate you being straight with me — that helps. I want to be equally direct: I'm very interested in this role, and I want to say yes. If the package is truly fixed, can you help me understand what the path looks like for an equity refresh or a level review once I'm in the seat? That context would make a real difference.
“Other candidates at this level are accepting the standard package.”
I'm sure that's true, and I'm not trying to be difficult. I just want to make sure we're starting in a place where I can be fully focused on the work from day one. The equity ask is the one thing that would get me there — is there any room at all on that number?
“I've genuinely valued this process and I have a lot of respect for the team — if the package isn't able to move on equity or signing, I'll need to take some time to weigh my options carefully, and I hope we can stay in touch regardless of how this lands.”
Targets are computed from your offer and a 5% base / 15% equity negotiation-room estimate; anchored to the DOL LCA market band for Massachusetts, where your base sits at roughly the 90th percentile; They are derived deterministically, not written by the model.
Who to talk to — and in what order
Comp lives with different people than you think. Aim each ask at the person who can actually move it.
Owns the offer number and can move base / signing within a set band.
Your first channel. Make the case here: give them the market floor and one clear, specific ask. Stay warm — they're your messenger, not your obstacle.
Owns level, scope, and the business case for hiring you.
Your advocate. Loop them in for a level bump, equity, or when the recruiter says the band is fixed — they can request an exception the recruiter can't.
Sets the salary bands; rarely negotiates with you directly.
You almost never talk to them. But the hiring manager can push an out-of-band exception up to them — which is why winning the manager matters.
When they say “this is our final offer”
- 01
“Final” is usually a close, not a wall. Stay gracious, restate your value in one line, and make a single specific, justified ask — not a list.
- 02
If base is capped, trade levers: pivot to a signing bonus, an equity refresh, an accelerated first review, or a title/level adjustment.
- 03
Only invoke a deadline or competing interest if it's real. A bluff that gets called costs you leverage and goodwill.
- 04
Give them an easy yes: name the one thing that turns a maybe into a signature today.
“I really want to make this work — I’m ready to sign. The one thing that would let me say yes today is [specific ask]. Is there any room there?”
RSU Grant Is Thin Relative to Role Scope; Push Toward $75,000–$80,000
The $55,000 RSU grant vesting over 3 years yields roughly $18,333 per year at current prices — a modest equity stake for a Global Job Level 11 director at a $142B company. PFE's DCF fair value is modeled at $38.37 versus the current price of $25.07, implying 53% upside to intrinsic value; even the analyst consensus target of $27 represents 7.7% appreciation. Request a grant increase to $80,000–$90,000 and frame it as alignment with the company's own recovery thesis — you're being asked to absorb current-price risk on a stock down 12.2% from its recent peak.
Evidence anchor: Computed metrics: DCF fair value $38.37, stock price $25.07, max drawdown -17.1%, current drawdown -12.2%; equity scenario base=$59,246 at $27
Base Is at Market Ceiling; Redirect Negotiation Energy Entirely to Equity
At $215,000, your base sits at the 90th percentile of the Massachusetts base-cash market band (median $162,634, n=203 DOL LCA filings). That ceiling limits upside from pushing base further without triggering internal equity concerns at Pfizer's banding structure. The more productive ask is increasing the signing bonus from $30,000 to $45,000–$50,000, which is a one-time cost Pfizer can book outside the salary band and which compensates for unvested equity or deferred comp you are leaving behind at your current employer.
Evidence anchor: DOL H-1B/LCA Massachusetts comp band: P25 $148,762, median $162,634, P75 $187,975 (n=203); candidate base $215,000 at 90th percentile
AI Strategic Priority Creates Organizational Reliance Argument for Larger Grant
Pfizer's Q1 2026 earnings call explicitly named AI as a key strategic priority — 'embedding the use of artificial intelligence across our company' in R&D, commercial, manufacturing, and enterprise functions. A Director of Clinical Data Science sitting at the intersection of AI and clinical R&D is directly on the critical path of that stated priority. Use this to negotiate explicit scope language: request that the offer letter or role charter reference AI/ML platform responsibilities, which strengthens your case for a Level 12 reclassification review within 12–18 months of start.
Evidence anchor: Pfizer Q1 FY2026 earnings transcript, strategic priorities; EARNINGS STRUCTURED data
6.9% Dividend Yield Signals Range-Bound Stock; Negotiate Accelerated Vesting Cliff as Structural Hedge
PFE's dividend yield is 6.9% (FY2025 annual ratio data), which signals a mature capital return profile rather than a high-growth equity story — the stock returned only 3.3% over the past 12 months. For a 3-year RSU vest, you are accepting meaningful time-value risk on a stock with 24.4% annualized volatility and a Rule of 40 score of only 23.5. A reasonable counter is to request a 2-year vest schedule or a 1-year cliff with monthly vesting thereafter, reducing your exposure to the stock's patent-cliff and pipeline execution risk without changing the grant's face value.
Evidence anchor: Computed metrics: dividend yield 6.9% (FY2025 ratios), stock 12mo% 3.3%, annualized volatility 24.4%, Rule of 40 23.5
CFO Transition Creates Brief Window to Close Candidates Quickly; Use It
Pfizer's CFO Dave Denton stepped down effective August 15, 2026, with Cecile Guegan named Interim CFO while a permanent search is conducted. C-suite transitions of this nature typically create a brief window where compensation decisions for senior hires are less scrutinized against prior-period benchmarks — the incoming finance leadership has not yet set a new cost-discipline posture. Pfizer simultaneously reaffirmed full-year 2026 revenue guidance of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, signaling the business is stable enough to absorb a modestly richer offer. Move quickly: once a permanent CFO is seated, discretionary comp flexibility typically tightens.
Evidence anchor: SEC 8-K filed 2026-06-18 (pfe-20260618.htm); Graph transition: Dave Denton departure 2026-08-15, Cecile Guegan hire 2026-08-16
Questions they cannot fake
- 1
The $55,000 RSU grant vests over 3 years, but PFE is trading at $25.07 — roughly 35% below the DCF fair value of $38.37 and 10% below the analyst consensus median of $27. What is the grant-date price used to calculate my share count, and does Pfizer offer any refresh grants or performance-based equity at the Director level that would let me participate in a recovery scenario?
Your RSU value is fixed in dollars at grant but delivered in shares priced at a depressed stock. If the grant price is set at or near current levels (~$25), the bear-case equity scenario is $59,246 and the bull case is $91,436 — a $32,000 spread over 3 years. Understanding the refresh cadence and whether performance RSUs exist at GL11 tells you whether the equity upside is structural or a one-time bet on a single grant.
- 2
Pfizer's headcount has declined from 88,000 at end-2023 to 75,000 at end-2025 — a 15% reduction in two years — and a WARN filing shows 100 workers separated in Washington state in August 2025. How has the Clinical Data Science organization specifically been sized over that period, and is the Cambridge GL11 headcount plan stable through 2027?
A Director role in a function that has been contracting carries different scope risk than one in a growing unit. The 13,000-person reduction is material. Knowing whether Clinical Data Science was a net gainer or loser in that restructuring — and whether the Metsera acquisition or AI embedding strategy is adding or displacing headcount in this function — directly affects your ability to build a team and deliver on the role's mandate.
- 3
Pfizer's CFO departed on August 15, 2026, with an interim CFO named and a permanent search underway. The company simultaneously reaffirmed full-year 2026 revenue guidance of $59.5–$62.5 billion. How does a CFO transition of this duration typically affect discretionary budget approvals for data science infrastructure and headcount at the Director level, and who is the budget authority for this function during the interim period?
CFO transitions at large pharma routinely trigger a 60–90 day budget freeze on non-committed spend. For a Director starting October 15, that window overlaps directly with your first quarter. Knowing the approval chain and whether your team's tooling, vendor contracts, or FTE requests are already committed versus pending protects you from walking into a scope that looks funded on paper but is frozen in practice.
- 4
Pfizer has named AI embedding as a key strategic priority, with the Q1 2026 earnings transcript citing R&D, commercial, manufacturing, and enterprise functions as active areas. Where does Clinical Data Science sit in that AI roadmap — specifically, is this role expected to build or govern AI/ML pipelines for clinical trials, and how is that work resourced relative to the broader Digital and Technology organization led by CIO Dennis Hancock?
The answer determines whether this is a high-visibility role with executive sponsorship and dedicated engineering resources, or a coordination role that depends on a separate technology org. At GL11, your ability to demonstrate impact — and justify a compensation review or promotion — depends heavily on whether you own outcomes or influence them. The distinction also affects whether the $215,000 base, which sits at the 90th percentile of the Massachusetts market band (median $162,634), is priced for a builder or a manager of vendor relationships.
Dealbreakers to watch
CFO Departure Creates Finance Leadership Vacuum at a Critical Juncture
highDave Denton stepped down as CFO effective August 15, 2026, replaced by an interim (Cecile Guegan, SVP Finance, Global Biopharmaceutical Business) while Pfizer conducts a full search. This is not a routine transition: it coincides with a Rule of 40 score of 23.5, a stock trading at $25.07 against a DCF fair value of $38.37, and a dividend payout ratio of 1.26× earnings (FY2025) that is mathematically unsustainable without earnings recovery. Finance leadership instability at this moment raises the probability of budget resets, headcount reviews, and equity plan modifications that could affect your unvested RSUs before the 3-year vest completes. Your $55,000 RSU grant vests over 36 months starting October 2026 — the bulk of that exposure sits in 2027–2029, precisely when a new permanent CFO will be setting capital allocation priorities.
Source ↗ · SEC 8-K filed 2026-06-18 (pfe-20260618.htm); Graph transition record confirmed departure 2026-08-15Headcount Contraction of 14,000 in Two Years Signals Ongoing Restructuring Exposure
highPfizer's 10-K filings show headcount fell from 88,000 (FY2023) to 81,000 (FY2024) to 75,000 (FY2025) — a 14.8% reduction in two years. A separate WARN Act filing in Washington state (August 2025, 100 workers) confirms active workforce reductions are not purely post-COVID normalization. The Q1 2026 earnings transcript noted the executive team itself was reduced by 4 members over two years. For a Director-level hire starting October 2026, this trajectory means your function, budget, and team size are not stable baselines — they are outputs of an ongoing cost optimization that has not yet concluded. Negotiate explicit headcount commitments or a scope-protection clause before accepting.
Source ↗ · SEC 10-K filings: FY2023 (filed 2024-02-22), FY2024 (filed 2025-02-27), FY2025 (filed 2026-02-26); WARN Act filing WA 2025-08-25RSU Grant Is Thin Relative to Equity Upside and Carries Meaningful Downside Risk
mediumYour $55,000 RSU grant at the current price of $25.07 represents approximately 2,193 shares. The bear/base equity scenario values this at $59,246 (at analyst consensus $27); the bull case reaches $91,436 only if the stock hits $41.67 — the high-end analyst target. The DCF fair value of $38.37 implies ~53% upside from current levels, but the stock has returned only 3.3% over the past 12 months against a peer-group median revenue growth of 5.5% (Pfizer's own growth: 5.4% — essentially in line but not leading). Annualized volatility is 24.4% with a max drawdown of -17.1% and a current drawdown of -12.2%. The dividend yield of ~6.9% (FY2025) is attractive but is being paid out of cash flow at a coverage ratio of 0.94× capex-plus-dividends — meaning the dividend itself competes with capital allocation. Push for a larger RSU grant (target $75,000–$85,000) or a performance-vesting overlay tied to non-COVID revenue growth, which ran at 7% operationally in Q1 2026.
Source ↗ · Computed equity scenarios (rsu_linear, spread 54.3%); PFE FY2025 10-K (filed 2026-02-26); Q1 2026 earnings transcriptArbutus LNP Patent Litigation Adds Unquantified Liability to an Already Leveraged Balance Sheet
mediumOn July 16, 2026, Arbutus and Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines. Pfizer's net debt-to-EBITDA stands at 3.75× (TTM), its Altman Z-score is 2.03 (distress zone below 1.81, caution zone 1.81–2.99 — Pfizer sits in the caution band), and its tangible book value is negative at -$6.73/share. Additional litigation exposure on a core platform technology is not priced into the base case. For a Clinical Data Science Director whose work likely touches vaccine and mRNA programs, this creates both organizational uncertainty (program prioritization shifts) and financial risk to the equity component of your package.
Source ↗ · GlobeNewsWire press release 2026-07-16; PFE FY2025 10-K (Altman Z 2.03, net debt/EBITDA 3.75×)
Canonical action signals
RSU Grant Is Thin; Push for More: The $55,000 RSU grant vesting over 3 years yields roughly $18,333 per year at current prices — a modest equity stake for a Global Job Level 11 director at a $142B company. PFE's DCF fair value is modeled at $38.37 versus the current price of $25.07, implying 53% upside to intrinsic value; even the analyst consensus target of $27 represents 7.7% appreciation. Request a grant increase to $80,000–$90,000 and frame it as alignment with the company's own recovery thesis — you're being asked to absorb current-price risk on a stock down 12.2% from its recent peak.
Evidence confidence: medium
Base Is Strong; Redirect Energy to Signing Bonus: At $215,000, your base sits at the 90th percentile of the Massachusetts base-cash market band (median $162,634, n=203 DOL LCA filings). That ceiling limits upside from pushing base further without triggering internal equity concerns at Pfizer's banding structure. The more productive ask is increasing the signing bonus from $30,000 to $45,000–$50,000, which is a one-time cost Pfizer can book outside the salary band and which compensates for unvested equity or deferred comp you are leaving behind at your current employer.
Evidence confidence: medium
AI Priority Creates Scope Negotiation Leverage: Pfizer's Q1 2026 earnings call explicitly named AI as a key strategic priority — 'embedding the use of artificial intelligence across our company' in R&D, commercial, manufacturing, and enterprise functions. A Director of Clinical Data Science sitting at the intersection of AI and clinical R&D is directly on the critical path of that stated priority. Use this to negotiate explicit scope language: request that the offer letter or role charter reference AI/ML platform responsibilities, which strengthens your case for a Level 12 reclassification review within 12–18 months of start.
Evidence confidence: medium
The $55,000 RSU grant vests over 3 years, but PFE is trading at $25.07 — roughly 35% below the DCF fair value of $38.37 and 10% below the analyst consensus median of $27. What is the grant-date price used to calculate my share count, and does Pfizer offer any refresh grants or performance-based equity at the Director level that would let me participate in a recovery scenario? Why: Your RSU value is fixed in dollars at grant but delivered in shares priced at a depressed stock. If the grant price is set at or near current levels (~$25), the bear-case equity scenario is $59,246 and the bull case is $91,436 — a $32,000 spread over 3 years. Understanding the refresh cadence and whether performance RSUs exist at GL11 tells you whether the equity upside is structural or a one-time bet on a single grant.
Evidence confidence: medium
Pfizer's headcount has declined from 88,000 at end-2023 to 75,000 at end-2025 — a 15% reduction in two years — and a WARN filing shows 100 workers separated in Washington state in August 2025. How has the Clinical Data Science organization specifically been sized over that period, and is the Cambridge GL11 headcount plan stable through 2027? Why: A Director role in a function that has been contracting carries different scope risk than one in a growing unit. The 13,000-person reduction is material. Knowing whether Clinical Data Science was a net gainer or loser in that restructuring — and whether the Metsera acquisition or AI embedding strategy is adding or displacing headcount in this function — directly affects your ability to build a team and deliver on the role's mandate.
Evidence confidence: medium
Pfizer's CFO departed on August 15, 2026, with an interim CFO named and a permanent search underway. The company simultaneously reaffirmed full-year 2026 revenue guidance of $59.5–$62.5 billion. How does a CFO transition of this duration typically affect discretionary budget approvals for data science infrastructure and headcount at the Director level, and who is the budget authority for this function during the interim period? Why: CFO transitions at large pharma routinely trigger a 60–90 day budget freeze on non-committed spend. For a Director starting October 15, that window overlaps directly with your first quarter. Knowing the approval chain and whether your team's tooling, vendor contracts, or FTE requests are already committed versus pending protects you from walking into a scope that looks funded on paper but is frozen in practice.
Evidence confidence: medium
By mid-2028, Pfizer's ongoing restructuring — which already eliminated 14,000 positions between FY2023 and FY2025 — reached the Clinical Data Science organization in Cambridge. The interim CFO who replaced Dave Denton in August 2026 approved a second wave of R&D cost reductions tied to the Arbutus LNP litigation settlement reserve and a slower-than-expected oncology pipeline conversion rate, and the Director-level Clinical Data Science headcount in Cambridge was cut from 12 to 7. The user's role was either eliminated outright or so severely scope-reduced — stripped of the AI/ML pipeline ownership that made the role attractive — that it became a data governance maintenance function, triggering a voluntary exit inside the 12-month signing bonus clawback window and forcing repayment of $30,000 at the worst possible moment.
Evidence confidence: medium
Pfizer announces a second WARN Act filing in Massachusetts or a Cambridge-specific headcount reduction in Clinical Data Science or the broader Digital and Technology organization before April 2027 — monitor the Massachusetts WARN Act database…
Evidence confidence: medium
The permanent CFO search extends beyond Q1 2027 without a named hire, or the incoming permanent CFO's first public action includes a revised 2027 cost-savings target above the existing $4.5B program — watch Pfizer 8-K filings and earnings call transcripts for any upward revision to the…
Evidence confidence: medium
Not available for this run: exit terms on the public record. Every stream we checked — rendered, held, or absent — is itemized in the appendix coverage matrix.
What this brief covers — and what it can’t
Public-company evidence: financial health and trajectory, leadership and board signals, role-level exposure (restructuring filings, WARN notices), the citable market wage band, insider filing patterns, and the negotiation math built from them.
Your future manager and team, day-to-day culture, benefit terms the filings don’t carry (the 401k match formula, PTO, parental leave, healthcare costs), and private-company comparisons. Where a DOL Form 5500 filing matched, the plan-level 401k facts appear above — the day-to-day terms still don’t. That’s what the verification questions in §6 are for — ask them before you sign.
Evidence and methodology
The main brief stays readable; the supporting facts, confidence map, source logs, methodology, and export preview live here for auditability.
Confidence and data gaps
- Career-path aggregates use optional user contributions; this report scores public filings only.
Sources cross-referenced
Data coverage
This tracks whether available evidence is rendered, held for methodology, gated by confidence, or unavailable.
Canonical verdict and one-number model
Canonical
Rendered in the executive decision screen.
Canonical section claims
Canonical · 51 items
Rendered across the guided chapters as concise evidence cards.
Supporting facts and methodology notes
Canonical · 36 items
Kept in the appendix so the main report stays readable.
Revenue product and geographic segmentation
Fetched · 5 items
Top segments are rendered in Company Quality; full rows remain source data.
Analyst estimates, grades, DCF, targets, earnings
Fetched
Rendered as market-consensus cards instead of raw analyst feeds.
News, press releases, and M&A events
Fetched · 6 items
Material recent events are summarized; raw feed clutter is omitted from the main flow.
Ownership concentration and financial health scores
Fetched
Rendered in Role and Career Risk when it changes the risk read.
Career signal layer leadership and board coverage
Computed
Rendered as leadership tape, coverage note, and board count.
O*NET, BEA, WARN, SEC facts, lobbying, USAspending, FEC
Open Data · 5 items
Verified public-data facts are rendered through canonical claims and the evidence appendix.
Evidence behind the dossier: supporting facts, methodology, confidence rationale, filing logs, and exportable rows. Empty sections describe what was reviewed rather than silently disappearing.
Supporting facts(36)
- Quarterly revenue (Q4 FY2024): $17763.0M.Company financial statements · high confidence · Q4 FY2024
- Quarterly revenue (Q1 FY2025): $13715.0M.Company financial statements · high confidence · Q1 FY2025
- Quarterly revenue (Q2 FY2025): $14653.0M.Company financial statements · high confidence · Q2 FY2025
- Quarterly revenue (Q3 FY2025): $16654.0M.Company financial statements · high confidence · Q3 FY2025
- Quarterly revenue (Q4 FY2025): $17557.0M.Company financial statements · high confidence · Q4 FY2025
- Rule of 40 score: 23.5. Revenue growth 5.4% + FCF margin 18.1%.Computed market metrics · high confidence · 2026-07-22T14:50:40.191Z
- Revenue per employee: $193K (+13.8% YoY).Computed market metrics · medium confidence · 2026-07-22T14:50:40.191Z
- Insider activity (90d): 1 open-market sells, 0 open-market buys, sell ratio 100%. Excluded as non-discretionary: 13 equity awards, 0 tax-withholding, 0 gifts. Pattern: opportunistic_selling. Signal: negative (low).Form 4 insider activity · medium confidence · 2026-07-22T14:52:46.546Z
- Equity scenario base case: analyst median implies $59,246 for the supplied grant.Equity scenario model · high confidence · 2026-07-22T14:50:40.191Z
- 12-month stock risk: annualized volatility 24.4%, max drawdown -17.1%, current drawdown -12.2%.Historical price model · high confidence · 2026-07-22T14:50:40.191Z
- Cecile Guegan hire: Interim Chief Financial Officer.SEC 8-K leadership event · medium confidence · 2026-08-16https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm
- Dave Denton departure: Chief Financial Officer.SEC 8-K leadership event · medium confidence · 2026-08-15https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm
- Board: 13 directors (11/13 independent).Proxy statement board record · medium confidence · 2026https://www.sec.gov/Archives/edgar/data/78003/000007800326000033/pfe-20260312.htm
- SEC filing: 4 filed 2026-07-16 00:00:00.SEC filing index · medium confidence · 2026-07-16 00:00:00https://www.sec.gov/Archives/edgar/data/78003/000122520826006638/xslF345X06/doc4.xml
- SEC filing: 4 filed 2026-07-13 00:00:00.SEC filing index · medium confidence · 2026-07-13 00:00:00https://www.sec.gov/Archives/edgar/data/78003/000122520826006587/xslF345X06/doc4.xml
- SEC filing: 4 filed 2026-07-01 00:00:00.SEC filing index · medium confidence · 2026-07-01 00:00:00https://www.sec.gov/Archives/edgar/data/78003/000122520826006273/xslF345X06/doc4.xml
- Strategic coherence: 75/100 (Strong). Strong focus on R&D and innovation suggests opportunities for growth in roles related to these areas.Earnings call transcript · high confidence · 2026-07-22T14:52:46.546Z
- Lobbying exposure: $20.39M reported over 40 filings. Top issues: HCR, TRD, TAX, MMM, PHA.Public lobbying disclosure · medium confidence · 2026-07-22T14:52:46.546Z
- Federal contract exposure: $0.02M obligated across 20 awards. Top agencies: Department of Defense.Federal contract disclosure · medium confidence · 2026-07-22T14:52:46.546Z
- Echevarria Joseph: option_exercise_hold (neutral).Insider activity classification · medium confidence · 2026-06-26
Confidence map(8)
- comp_reality · high Section has source-backed facts available.
- leverage · medium Section has source-backed facts available.
- leadership_stability · medium Section has source-backed facts available.
- three_questions · medium Section has source-backed facts available.
- counterfactual · low Counterfactual recommender needs alumni outcomes and peer score generation.
- five_year_forecast · low Career-path aggregates use optional user contributions; this report scores public filings only.
- organizational_diagnosis · medium Section has source-backed facts available.
- red_flags · medium Section has source-backed facts available.
Methodology(10)
- Trajectory Score weights organizational health, leadership stability, strategic coherence, alumni outcomes, promotion velocity, skills marketability, and role-specific risk.
- One Number model varies by report mode: NPV for offer evaluation, EV delta for stay-or-go, trajectory percentile for job seekers, CCVI for career trajectory.
- Public-source leadership signals come from SEC 8-K and DEF 14A records when available.
- Leadership coverage: ready. Leadership=ready, board=ready, transitions=ready. 21 role records, 13 board records, 2 transition records.
- Ticker: PFE. Company: Pfizer Inc..
- Offer inputs: base $215,000, equity $55,000.
- No user-contributed tenure aggregates available.
- Cross-section findings are AI-generated from assembled Tier 2 data and validated for multi-section citation.
- Pre-mortem output was generated by Footnote's structured risk model.
- Insider sentiment aggregate was not available for this ticker.
8-K leadership log(2)
[
{
"new_role": "Interim Chief Financial Officer",
"source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm",
"former_role": null,
"person_name": "Cecile Guegan",
"source_quote": "will serve as Interim Chief Financial Officer",
"effective_date": "2026-08-16",
"prior_employer": "Pfizer",
"transition_type": "hire"
},
{
"new_role": null,
"source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm",
"former_role": "Chief Financial Officer",
"person_name": "Dave Denton",
"source_quote": "he will step down from his current position as Chief Financial Officer",
"effective_date": "2026-08-15",
"prior_employer": null,
"transition_type": "departure"
}
]Insider trading log(100)
[
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006638/0001225208-26-006638-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-07-16",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772901,
"transactionDate": "2026-07-15",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 24,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006587/0001225208-26-006587-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-07-13",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772938,
"transactionDate": "2026-07-09",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 84,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006273/0001225208-26-006273-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-07-01",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772979,
"transactionDate": "2026-06-30",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 25,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006260/0001225208-26-006260-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0002041310",
"securityName": "Phantom Stock Units",
"reportingName": "Buckley Mortimer J",
"securitiesOwned": 26335.128,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1543.845,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006259/0001225208-26-006259-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001633137",
"securityName": "Phantom Stock Units",
"reportingName": "Echevarria Joseph",
"securitiesOwned": 165631.508,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1904.076,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006258/0001225208-26-006258-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001224154",
"securityName": "Phantom Stock Units",
"reportingName": "NARAYEN SHANTANU",
"securitiesOwned": 200879.336,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 2058.46,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006257/0001225208-26-006257-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001611777",
"securityName": "Phantom Stock Units",
"reportingName": "SMITH JAMES C",
"securitiesOwned": 182886.001,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1852.614,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006256/0001225208-26-006256-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001561264",
"securityName": "Phantom Stock Units",
"reportingName": "Quincey James",
"securitiesOwned": 87993.957,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1595.307,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006255/0001225208-26-006255-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-30",
"typeOfOwner": "director",
"reportingCik": "0001454920",
"securityName": "Phantom Stock Units",
"reportingName": "Taraporevala Cyrus",
"securitiesOwned": 36941.287,
"transactionDate": "2026-06-26",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 1543.845,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006072/0001225208-26-006072-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-16",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772772,
"transactionDate": "2026-06-15",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 23,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826005911/0001225208-26-005911-index.htm",
"price": 25.7,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-10",
"typeOfOwner": "officer: SVP & Controller",
"reportingCik": "0001805617",
"securityName": "Common Stock",
"reportingName": "DAMICO JENNIFER B.",
"securitiesOwned": 31397,
"transactionDate": "2026-06-09",
"transactionType": "S-Sale",
"directOrIndirect": "D",
"securitiesTransacted": 2000,
"acquisitionOrDisposition": "D"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826005687/0001225208-26-005687-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-06-01",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 772789,
"transactionDate": "2026-05-29",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 23,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826005449/0001225208-26-005449-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-05-18",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 773297,
"transactionDate": "2026-05-15",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 24,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004835/0001225208-26-004835-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-05-04",
"typeOfOwner": "director, officer: Chairman & CEO",
"reportingCik": "0001595703",
"securityName": "Phantom Stock Units SSP",
"reportingName": "BOURLA ALBERT",
"securitiesOwned": 760229,
"transactionDate": "2026-04-30",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 22,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004663/0001225208-26-004663-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001411359",
"securityName": "Phantom Stock Units",
"reportingName": "Gottlieb Scott",
"securitiesOwned": 57001.814,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004662/0001225208-26-004662-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001310264",
"securityName": "Phantom Stock Units",
"reportingName": "NORA JOHNSON SUZANNE M",
"securitiesOwned": 116982.649,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004661/0001225208-26-004661-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001733004",
"securityName": "Phantom Stock Units",
"reportingName": "LITTMAN DAN R.",
"securitiesOwned": 74533.568,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004660/0001225208-26-004660-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001214686",
"securityName": "Phantom Stock Units",
"reportingName": "BLAYLOCK RONALD E",
"securitiesOwned": 84012.66,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004659/0001225208-26-004659-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0002041310",
"securityName": "Phantom Stock Units",
"reportingName": "Buckley Mortimer J",
"securitiesOwned": 24391.124,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
},
{
"url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826004658/0001225208-26-004658-index.htm",
"price": 0,
"symbol": "PFE",
"formType": "4",
"companyCik": "0000078003",
"filingDate": "2026-04-27",
"typeOfOwner": "director",
"reportingCik": "0001507911",
"securityName": "Phantom Stock Units",
"reportingName": "Desmond-Hellmann Susan",
"securitiesOwned": 45635.605,
"transactionDate": "2026-04-23",
"transactionType": "A-Award",
"directOrIndirect": "D",
"securitiesTransacted": 7686.539,
"acquisitionOrDisposition": "A"
}
]Transcript pull(6)
“Execute on financial commitments while investing for future growth · Deliver 2026 critical R&D milestones · Maximize value of Metsera acquisition for obesity therapies · Embed artificial intelligence across the company”
Investment priority“While we remain focused on managing near-term LOE headwinds, we are actively building the foundation for durable long-term value creation.”
Stated risk · LOE Headwinds“Sustained low disease levels of COVID will likely continue to weigh on Paxlovid utilization over the next several months.”
Stated risk · COVID Product Sales“Roughly half of our anticipated key data readouts and regulatory decision in 2026 are expected to come from oncology.”
Investment priority · Oncology“We are targeting approximately 20 pivotal study starts, 8 key data readouts and 4 regulatory decisions this year.”
Investment priority · Metabolic Disease“We have been working with regulators on the pathway for expanding coverage through our next-generation pneumococcal conjugate vaccine.”
Investment priority · Vaccines
Glossary(4)
- 8-K
- SEC current report used for material company events, including executive appointments and departures.
- DEF 14A
- Definitive proxy statement containing board, governance, and executive disclosure.
- Trajectory Score
- Footnote's 0-100 estimate of career value and risk for a role/company decision.
- K-anonymity
- Privacy threshold that suppresses aggregate user-contributed metrics until enough contributors exist.
Export preview
CSV preview — first 10 rows of 36, exactly as the download serializes them.
id,claim,value,source_type,confidence fact_001,Quarterly revenue (Q4 FY2024): $17763.0M.,17763000000,fmp_financials,high fact_002,Quarterly revenue (Q1 FY2025): $13715.0M.,13715000000,fmp_financials,high fact_003,Quarterly revenue (Q2 FY2025): $14653.0M.,14653000000,fmp_financials,high fact_004,Quarterly revenue (Q3 FY2025): $16654.0M.,16654000000,fmp_financials,high fact_005,Quarterly revenue (Q4 FY2025): $17557.0M.,17557000000,fmp_financials,high fact_006,Rule of 40 score: 23.5. Revenue growth 5.4% + FCF margin 18.1%.,23.5,derived_fmp,high fact_007,Revenue per employee: $193K (+13.8% YoY).,192680,derived_fmp,medium fact_008,"Insider activity (90d): 1 open-market sells, 0 open-market buys, sell ratio 100%. Excluded as non-discretionary: 13 equity awards, 0 tax-withholding, 0 gifts. Pattern: opportunistic_selling. Signal: negative (low).",1,fmp_insider_trading,medium fact_009,"Equity scenario base case: analyst median implies $59,246 for the supplied grant.",59246,derived_equity_scenario,high fact_010,"12-month stock risk: annualized volatility 24.4%, max drawdown -17.1%, current drawdown -12.2%.",'-17.1,derived_price_history,high
JSON export contents (keys): facts, sections
Purchase your report to unlock full details
Live SEC filings, peer comp, scripts, provenance, and canonical synthesis — built for your company and offer.
Get the Offer Brief — $49See all four brief tiers